Head of the Graduate School at St George's, University of London.
President of the Israel Academy of Sciences & Humanities. Former VP of the Weizmann Institute of Science. Significant contributions to vaccine development, cancer research & parasitic diseases. Has served as President of EFIS and Secretary-General of the IUIS. Awards include the Robert Koch Prize in Medical Sciences, Spain’s Diaz Memorial Prize, France's Legion of Honor, the Hadassah World Organization's Women of Distinction Award, the Wolf Prize for Medicine, the Rothschild Prize for Biology.
Professor of Immunology and Basic Oncology; Center for Molecular Medicine and Stem Cells Research, Faculty of Medical Sciences, University of Kragujevac.
I am a Professor and Chair, Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Egypt. I am interested in microbiome research, pharmacomicrobiomics, evolution and emergence microbial pathogenesis and resistance, microbial and phage genomics, antibiotic resistance surveillance, adaptive laboratory evolution, metabolic reconstruction and pathway gap filling, and virulence gene discovery.
Professor of Thoracic Medicine at the National Heart and Lung Institute, Head of Respiratory Medicine at Imperial College & Honorary Consultant Physician at Royal Brompton Hospital, London. Has been the most highly cited clinical scientist in Europe & the most highly cited respiratory researcher in the world over the last 20 years. Elected a Fellow of the Royal Society in 2007. Currently a member of the Scientific Committee of the WHO/NIH global guidelines on asthma (GINA) and COPD (GOLD).
Barnes is the author of over 1,000 publications in peer reviewed journals. He has edited or co-edited over 50 books on asthma, COPD and respiratory pharmacology.
He has been received honorary degrees from the Universities of Ferrara (Italy), Athens (Greece), Tampere (Finland), Leuven (Belgium) and Maastricht (Netherlands). He co-founded an Imperial spin-out company RespiVert, which was acquired by Johnson & Johnson and has developed novel inhaled treatments for COPD and severe asthma.
Prof. Becker is heading the Department of Translational Oncology at the Westdeutsches Tumorzentrum in Essen with a focus on skin cancer research.
Jürgen C. Becker received his medical degree from the Medical School Hannover for his work on the immune regulatory capacity of natural killer cells on the adaptive immune system. After finishing medical school he was first trained in Dermatology at the University of Würzburg and then as well in Tumor Immunology at the Scripps Research Institute, La Jolla, and the Danish Cancer Society, Copenhagen. For his characterization of the impact of therapeutic interventions on the adaptive immune responses against melanoma in preclinical models he received the PhD in Immunology. In 2003 he became full professor for Dermato-Oncology in Würzburg, where he coordinated a Clinical Research Group focusing on the tumor microenvironment. In 2010, he was appointed as director of General Dermatology at the Medical University of Graz. There, in parallel to his clinical duties, he successfully attracted the FP7 EU-project IMMOMEC (IMmune MOdulating strategies for treatment of MErkel cell Carcinoma, www.immomec.eu) and became deputy speaker of the graduate training program DK-MOLIN (Doktoratskolleg MOLecular fundamentals of INflammation, www.medunigraz.at/DK-MOLIN/).
Regental Professor and Director of the Center for the Genetics of Host Defense at the UT Southwestern Medical Center in Dallas, Texas. Member of the National Academy of Sciences and the Institute of Medicine. Recipient of many awards, including the 2011 Nobel Prize for Medicine; the 2011 Shaw Prize; the 2009 Will Rogers Institute Annual Prize; the 2009 Albany Medical Center Prize; the 2007 Balzan Prize and the 2004 Robert Koch Prize. (Photo by Brian Coats for UT Southwestern Med Ctr)
A.W. and Mary Margaret Clausen Distinguished Professor and Director, Hormone Research Institute. Serves on the Science Translational Medicine advisory board and founding Director, Immune Tolerance Network. A recipient of a Guggenheim Fellowship and elected member of the Academy of Arts and Sciences and National Academy of Medicine. Dr. Bluestone has spent over 35 years working as an immunologist interested in immune tolerance as it relates to autoimmunity and organ transplantation.
Obtained her PhD degree in the University of Paris VII in 1993, and trained as a post-doc in Prof. John Dick’s group in Toronto. In 1998, she became Group Leader at the Coriell Institute for Medical Research and Assistant Professor, University of Medicine and Dentistry of New Jersey. In 2001, she joined the London Research Institute. Since 2002, she is also Professor, University College of London and Senior Lecturer at the Institute of Child Health.
Dr. Vincenzo Brancaleone is Assistant Professor of Pharmacology, Department of Science, University of Basilicata.
Dr. Brancaleone main research field includes:
1) vascular biology in vivo and in vitro in physiopathological conditions related to gaseous mediators: role of nitric oxide (NO) and hydrogen sulfide (H2S);
2) role of sphingosine-1-kinase/sphingosine-1-phosphate (S1PK/S1P) pathway in vascular, respiratory and inflammatory processes;
3) role of Annexin A1 and its receptor (Formylated Peptide Receptor 2, FPR2) in resolving mechanism in inflammation.
Dr. Brancaleone is full member of British Pharmacological Society (BPS) and Italian Society of Pharmacology (SIF).
He performs reviewer activity for international relevant and impacted scientific journal: Mediators of Inflammation (IF:3.263), British Journal of Pharmacology (IF:4.409), Inflammation Research (IF:2.109), Diabetes & Vascular Disease Research (IF:2.116), FasebJ (IF:5.299)
Dunja Bruder did her PhD thesis in immunology focussing on T cell responses to bacterial toxins (1996-1999) followed by a postdoc in the field of mucosal immunology at the HZI in Braunschweig (2000-2006). After several scientific stays abroad (Harvard Medical School; Yale University School of Medicine) she became head of the research group “Immune Regulation” at the HZI (2006). In addition, since 2011 Dunja Bruder is Professor for "Infection Immunology" at the University Hospital in Magdeburg.
Alessandra Cambi received a Ph.D in Biology at the University of Camerino (Italy) and a Ph.D in Medical Sciences (cum laude) at the Radboud University Nijmegen (The Netherlands). After a long-term EMBO postdoctoral fellowship at the Max Planck Institute of Biphysical Chemistry (Germany) and a VENI fellowship from the Dutch Scientific Organization (NWO), she became junior group leader. She is currently associate professor and group leader of the Nano-Immunology group in Nijmegen.